Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Yкраїнський (UK)
Przejdź do strony domowej biblioteki Centralna Biblioteka Wojskowa Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaCentralna Biblioteka Wojskowa

Wyszukujesz frazę "gene- therapy" wg kryterium: Wszystkie pola

  Lista filtrów
Wyrównaj
Wyświetlanie 1-15 z 37
Tytuł:
Adeno-associated virus vector-mediated gene delivery to the vasculature and kidney.
Autorzy:
Kapturczak, Matthias
Chen, Sifeng
Agarwal, Anupam
Powiązania:
https://bibliotekanauki.pl/articles/1041403.pdf
Data publikacji:
2005
Wydawca:
Polskie Towarzystwo Biochemiczne
Tematy:
kidney
vasculature
viral vectors
endothelium
recombinant adeno-associated virus
gene therapy
Opis:
Relatively successful elsewhere, gene delivery aimed at the vasculature and kidney has made very little progress. In the kidney, the hurdles are related to the unique structure–function relationships of this organ and in the blood vessels to a variety of, mostly endothelial, factors making the delivery of transgenes very difficult. Among gene-therapeutic approaches, most viral gene delivery systems utilized to date have shown significant practical and safety-related limitations due to the level and duration of recombinant transgene expression as well as their induction of a significant host immune response to vector proteins. Recombinant adeno-associated virus (rAAV) vectors appear to offer a vehicle for safe, long-term transgene expression. rAAV-based vectors are characterized by a relative non-immunogenicity and the absence of viral coding sequences. Furthermore, they allow for establishment of long-term latency without deleterious effects on the host cell. This brief review addresses problems related to transgene-delivery to kidney and vasculature with particular attention given to rAAV vectors. The potential for gene therapy as a strategy for selected renal and vascular diseases is also discussed.
Źródło:
Acta Biochimica Polonica; 2005, 52, 2; 293-299
0001-527X
Pojawia się w:
Acta Biochimica Polonica
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Antiangiogenic gene therapy in inhibition of metastasis.
Autorzy:
Szala, Stanisław
Szary, Jarosław
Cichoń, Tomasz
Sochanik, Aleksander
Powiązania:
https://bibliotekanauki.pl/articles/1043756.pdf
Data publikacji:
2002
Wydawca:
Polskie Towarzystwo Biochemiczne
Tematy:
antiangiogenic gene therapy
encapsulation
inducible gene expression
metastasis
Opis:
This short review attempts to demonstrate the usefulness of antiangiogenic gene therapy in achieving inhibition of growth in experimentally-induced metastases. Certain normal tissues (for example skeletal muscle) may be used in vivo, after genetic modification, as a "bioreactor", able to produce and secrete into the bloodstream proteins known to exert antiangiogenic effects. By inhibiting neoangiogenesis these proteins would thus prevent the development of metastases. The review discusses also the perspectives of antimetastatic therapy based on certain types of allogenic cells (for example myoblasts and fibroblasts) that had been genetically modified and then microencapsulated. The strategy of encapsulation is aimed at protecting the modified cells secreting antiangiogenic factors from being eliminated by the immune system. Secretion of antiangiogenic proteins by these microencapsulated cells can be controlled with inducible promoters. Antiangiogenic genes remaining under the transcriptional control of such promoters may be switched on and off using antibiotics, such as tetracycline derivatives, or steroid hormones.
Źródło:
Acta Biochimica Polonica; 2002, 49, 2; 313-321
0001-527X
Pojawia się w:
Acta Biochimica Polonica
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Antitumour activity of Salmonella typhimurium VNP20047 in B16(F10) murine melanoma model.
Autorzy:
Jazowiecka-Rakus, Joanna
Szala, Stanisław
Powiązania:
https://bibliotekanauki.pl/articles/1041570.pdf
Data publikacji:
2004
Wydawca:
Polskie Towarzystwo Biochemiczne
Tematy:
cancer gene therapy
tumour targeting
cytosine deaminase
Salmonella
Opis:
A tumour therapy is proposed based on attenuated Salmonella typhimurium VNP20047 expressing the Escherichia coli cytosine deaminase gene. VNP20047 was administered intravenously to B16(F10) melanoma-bearing C57BL/6 mice. VNP20047 proliferated within tumours and livers regardless of the initial inoculum dose. After 10 days the number of bacteria increased in livers up to 4.2 × 106 cfu/g and decreased in tumours down to 5.9 × 106 cfu/g. VNP20047 at 1 × 105 cfu/mouse, when combined with 5-fluorocytosine, inhibited tumour growth by 85% without prolonging animal survival. Histology studies revealed severe lesions in tumours and livers. These data suggest that S. typhimurium VNP20047 induced inflammatory responses, even though the strain was attenuated.
Źródło:
Acta Biochimica Polonica; 2004, 51, 3; 851-856
0001-527X
Pojawia się w:
Acta Biochimica Polonica
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Cancer immunotherapy using cells modified with cytokine genes.
Autorzy:
Kowalczyk, Dariusz
Wysocki, Piotr
Mackiewicz, Andrzej
Powiązania:
https://bibliotekanauki.pl/articles/1043434.pdf
Data publikacji:
2003
Wydawca:
Polskie Towarzystwo Biochemiczne
Tematy:
cancer
cancer vaccines
cytokines
dendritic cells
gene therapy
Opis:
The ability of various cytokines to hamper tumor growth or to induce anti-tumor immune response has resulted in their study as antitumor agents in gene therapy approaches. In this review we will concentrate on the costimulation of antitumor immune responses using modification of various cell types by cytokine genes. Several strategies have emerged such as (i) modification of tumor cells with cytokine genes ex vivo (whole tumor cell vaccines), (ii) ex vivo modification of other cell types for cytokine gene delivery, (iii) delivery of cytokine genes into tumor microenvironment in vivo, (iv) modification of dendritic cells with cytokine genes ex vivo. Originally single cytokine genes were used. Subsequently, multiple cytokine genes were applied simultaneously, or in combination with other factors such as chemokines, membrane bound co-stimulatory molecules, or tumor associated antigens. In this review we discuss these strategies and their use in cancer treatment as well as the promises and limitations of cytokine based cancer gene therapy. Clinical trials, including our own experience, employing the above strategies are discussed.
Źródło:
Acta Biochimica Polonica; 2003, 50, 3; 613-624
0001-527X
Pojawia się w:
Acta Biochimica Polonica
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
CEA-negative glioblastoma and melanoma cells are sensitive to cytosine deaminase/5-fluorocytosine therapy directed by the carcinoembryonic antigen promoter.
Autorzy:
Dąbrowska, Anna
Szary, Jarosław
Kowalczuk, Małgorzata
Szala, Stanisław
Ugorski, Maciej
Powiązania:
https://bibliotekanauki.pl/articles/1041550.pdf
Data publikacji:
2004
Wydawca:
Polskie Towarzystwo Biochemiczne
Tematy:
CEA promoter
E. coli cytosine deaminase
gene-directed enzyme prodrug therapy
Opis:
Recent studies have suggested that carcinoembryonic antigen (CEA)-promoter sequences are active only in CEA-positive cells, filing in the criteria for tumor specific targeting of suicide genes. However, the present study on gene therapy of colon cancer and cell-specificity of CEA promoter, provide evidence that CEA-positive and CEA-negative cells transfected with E. coli cytosine deaminase (CD) gene under the control of CEA promotor sequence are sensitive to enzyme/pro-drug therapy with 5-fluorocytosine (5-FC). Individual clones derived from the CEA-negative cell lines: melanoma Hs294T and glioblastoma T98G after transfection with CD differed profoundly in their sensitivity to 5-FC. The IC50 values for several clones of the CEA-negative cells were almost the same as for CEA-positive colon cancer cells. Such 5-FC-sensitive clones derived from the population of CEA-negative cells, present even in small number, because of the very effective bystender effect of this enzyme/pro-drug system can cause severe problems during therapy by efficiently killing surrounding normal cells. Safety is the major issue in gene therapy. Our data suggest that the safety of gene-directed enzyme pro-drug therapy (GDEPT) with CEA promoter driven expression of therapeutic genes is not so obvious as it has originally been claimed.
Źródło:
Acta Biochimica Polonica; 2004, 51, 3; 723-732
0001-527X
Pojawia się w:
Acta Biochimica Polonica
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Charakterystyka nanostrukturalna materiału genetycznego do zastosowania w terapii genowej
Nanostructural characteristics of genetic material for gene therapy application
Autorzy:
Duda, M.
Frączkowska, K.
Przybyło, M.
Kopaczyńska, M.
Powiązania:
https://bibliotekanauki.pl/articles/261139.pdf
Data publikacji:
2015
Wydawca:
Politechnika Wrocławska. Wydział Podstawowych Problemów Techniki. Katedra Inżynierii Biomedycznej
Tematy:
kondensacja DNA
spermidyna
terapia genowa
mikroskopia sił atomowych
DNA condensation
spermidine
gene therapy
atomic force microscopy (AFM)
Opis:
Terapia genowa jest obecnie bardzo dynamicznie rozwijającą się techniką biomedyczną, która może znaleźć zastosowanie w medycynie w leczeniu chorób przewlekłych i dziedzicznych. Badania skupiają się na opracowywaniu nowych strategii dotyczących procesów kondensacji i ochrony materiału genetycznego (DNA) wprowadzanego do komórki docelowej. Struktura i stopień upakowania dostarczanego DNA wpływają na kluczowe właściwości fizykochemiczne, determinujące czy wprowadzony wektor rekombinowany ulegnie ekspresji, czy też degradacji. Związki chemiczne, zwane czynnikami kondensującymi, to substancje powodujące zwinięcie DNA, a stopień kondensacji materiału genetycznego zależy bezpośrednio od rodzaju i stężenia użytego czynnika kondensującego. Do cząsteczek wykazujących właściwości kondensujące należą poliaminy, w opisywanym eksperymencie zastosowano poliaminę – spermidynę. Przeprowadzone badania miały na celu charakterystykę nanostrukturalną materiału genetycznego pod wpływem działania czynnika kondensującego. W wyniku analizy wykonanej za pomocą mikroskopii sił atomowych (AFM) wykazano, że plazmid DNA ulega kondensacji pod wpływem spermidyny, formując struktury rozetowe.
Gene therapy is a new promising method that may find many applications in modern biomedicine. Especially, it may be a powerful tool in chronic and hereditary diseases treatment. Current studies focus on development of novel strategies concerning genetic material (DNA) condensation and protection, whilst it is introduced into the cellular nucleus. Once the DNA enters the cell, it’s either passed on and expressed in the nucleus or degraded by intracellular nucleases. The structure and the degree of compaction influence physicochemical properties that determine what will happen to delivered genetic material. DNA coiling can be caused by chemical compounds called compaction agents, such as polyamines like spermidine used in this study. The aim of this research was to examine the nanostructural characteristics of genetic material exposed to compaction agent. The measurements and analysis performed by atomic force microscopy (AFM) indicate that DNA plasmid undergoes condensation and forms rosette-like structures once subjected to spermidine.
Źródło:
Acta Bio-Optica et Informatica Medica. Inżynieria Biomedyczna; 2015, 21, 1; 1-8
1234-5563
Pojawia się w:
Acta Bio-Optica et Informatica Medica. Inżynieria Biomedyczna
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Combination of IL-12 gene therapy and CTX chemotherapy inhibits growth of primary B16(F10) melanoma tumors in mice
Autorzy:
Mitrus, Iwona
Delić, Klaudia
Wróbel, Natalia
Missol-Kolka, Ewa
Szala, Stanisław
Powiązania:
https://bibliotekanauki.pl/articles/1041249.pdf
Data publikacji:
2006
Wydawca:
Polskie Towarzystwo Biochemiczne
Tematy:
antiangiogenic therapy
interleukin-12 gene
combined therapy
Opis:
We investigated suppression of murine B16(F10) melanoma tumor growth following a therapy which involved concomitant administration of cyclophosphamide and plasmid DNA bearing interleukin-12 gene. Since both therapeutic factors display antiangiogenic capabilities, we assumed that their use in blocking the formation of new blood vessels would result in augmented inhibition of tumor growth. This combined therapy regimen indeed resulted in a considerable suppression of tumor growth. We observed a statistically significant extension of treated animals' lifespan. Interestingly, the therapeutic effect was also obtained using a plasmid without an interleukin gene insert. This observation suggests that plasmid DNA, which has been widely applied for treating neoplastic tumors, contains element(s) that elicit immune response in mice.
Źródło:
Acta Biochimica Polonica; 2006, 53, 2; 357-360
0001-527X
Pojawia się w:
Acta Biochimica Polonica
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Combination of vasostatin gene therapy with cyclophosphamide inhibits growth of B16(F10) melanoma tumours
Autorzy:
Jazowiecka-Rakus, Joanna
Jarosz, Magdalena
Szala, Stanisław
Powiązania:
https://bibliotekanauki.pl/articles/1041289.pdf
Data publikacji:
2006
Wydawca:
Polskie Towarzystwo Biochemiczne
Tematy:
angiogenesis
combination
vasostatin
cyclophosphamide
gene therapy
Opis:
Angiogenesis, i.e. formation of new blood vessels out of pre-existing capillaries, is essential to the development of tumour vasculature. The discovery of specific antiangiogenic inhibitors has important therapeutic implications for the development of novel cancer treatments. Vasostatin, the N-terminal domain of calreticulin, is a potent endogenous inhibitor of angiogenesis and tumour growth. In our study, using B16(F10) murine melanoma model and electroporation we attempted intramuscular transfer of human vasostatin gene. The gene therapy was combined with antiangiogenic drug dosing schedule of a known chemotherapeutic (cyclophosphamide). The combination of vasostatin gene therapy and cyclophosphamide administration improved therapeutic effects in melanoma tumours. We observed both significant inhibition of tumour growth and extended survival of treated mice. To our knowledge, this is one of the first reports showing antitumour efficacy of electroporation-mediated vasostatin gene therapy combined with antiangiogenic chemotherapy.
Źródło:
Acta Biochimica Polonica; 2006, 53, 1; 199-202
0001-527X
Pojawia się w:
Acta Biochimica Polonica
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Combined delivery of an antiangiogenic protein (angiostatin) and an immunomodulatory gene (interleukin-12) in the treatment of murine cancer.
Autorzy:
Wilczyńska, Urszula
Kucharska, Anna
Szary, Jarosław
Szala, Stanisław
Powiązania:
https://bibliotekanauki.pl/articles/1044050.pdf
Data publikacji:
2001
Wydawca:
Polskie Towarzystwo Biochemiczne
Tematy:
angiogenesis
IL-12 gene
tumor gene therapy
angiostatin
Opis:
We investigated the feasibility of a novel therapeutic approach to treat neoplastic diseases in mice. This novel strategy consists in delivering a protein (angiostatin) with strong antiangiogenic properties, followed by administration of the interleukin 12 gene that is strongly immunomodulatory and has also some antiangiogenic effects. When angiostatin-mediated antiangiogenic therapy was used in combination with intratumor delivery of the IL-12 gene (a strategy much safer than IL-12 protein administration), this produced a synergistic therapeutic effect.
Źródło:
Acta Biochimica Polonica; 2001, 48, 4; 1077-1084
0001-527X
Pojawia się w:
Acta Biochimica Polonica
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Construction of a bicistronic proangiogenic expression vector and its application in experimental angiogenesis in vivo.
Autorzy:
Małecki;, Maciej
Przybyszewska, Małgorzata
Janik, Przemysław
Powiązania:
https://bibliotekanauki.pl/articles/1043468.pdf
Data publikacji:
2003
Wydawca:
Polskie Towarzystwo Biochemiczne
Tematy:
angiogenesis
gene therapy
bicistronic vectors
Opis:
Manipulation of angiogenesis in vivo is an example of successful gene therapy strategies. Overexpression of angiogenic genes like VEGF, FGF or PDGF causes new vessel formation and improves the clinical state of patients. Gene therapy is a very promising procedure but requires large amounts of pharmaceutical-grade plasmid DNA. In this regard we have constructed a bicistronic plasmid DNA vector encoding two proangiogenic factors, VEGF165 and FGF-2. The construct (pVIF) contains the internal ribosome entry site (IRES) of the encephalomyocarditis virus (ECMV) which permits both genes to be translated from a single bicistronic mRNA. The IRES sequence allows for a high efficiency of gene expression in vivo. The pVIF vector was characterized in vitro and in vivo. In vivo angiogenesis studies showed that the bicistronic vector encoding two proangiogenic factors induces the formation of new vessels significantly more than pVEGF165 or pFGF-2 alone. In our opinion the combined proangiogenic approach with VEGF165 and FGF-2 is more powerful and efficient than single gene therapy. We also postulate that IRES sequence can serve as a useful device improving efficiency of gene therapy.
Źródło:
Acta Biochimica Polonica; 2003, 50, 3; 875-882
0001-527X
Pojawia się w:
Acta Biochimica Polonica
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Czy „cichy” polimorfizm pojedynczego nukleotydu (SNP) C1236T genu ABCB1 jest związany z predyspozycją do rozwoju depresji i skutecznością jej leczenia? - badanie wstępne
Is the „silent” single nucleotide polymorphism (SNP) C1236T of ABCB1 gene associated with predisposition to depression development and efficiency of therapy? – preliminary study
Autorzy:
Jeleń, Agnieszka
Koziróg, Anna
Sałagacka, Aleksandra
Balcerczak, Ewa
Talarowska, Monika
Gałecki, Piotr
Powiązania:
https://bibliotekanauki.pl/articles/1032546.pdf
Data publikacji:
2014
Wydawca:
Łódzkie Towarzystwo Naukowe
Tematy:
abcb1
polimorfizm pojedynczego nukleotydu
c1236t
glikoproteina p
depresja
farmakogenomika
podatność
single nucleotide polymorphism
p-glycoprotein
depression
pharmacogenomics
susceptibility
Opis:
Introduction: According to the World Health Organization about 350 million people around the world are affected by depression. Despite the high prevalence of this disease the mechanism of depression origination as well as the causes of the resistance to therapy are still not fully understood. ABCB1 gene encode P glycoprotein which is one of the components of blood-brain barrier. The main function of this protein is the efflux of many toxic compounds, including drugs, which may indicate potential association between the proper functioning of P glycoprotein and the susceptibility to the development of depressive disorders or the failure of antidepressant therapy. The objective of this study was to evaluate single nucleotide polymorphism (SNP) C1236T of the ABCB1 gene in the group of patients with recurrent depressive disorder (rDD) and to estimate the possible association of this polymorphism with the response to antidepressant therapy. Material and methods: C1236T was evaluated in 30 patients with rDD. Genotyping was performed using automated sequencing (the Sanger method). The results were compared with those obtained from the control group which consisted of 96 blood donors from the local blood bank. Results: No statistically significant difference in the frequency of genotypes (p=0.0665) and allele (p=0.1489) for the SNP C1236T of ABCB1 gene was found between the patients with rDD and the control group. No correlation between C1236 and the age when the disease was stated (p=0.0807). Neither the association between genotypes and the severity of depressive symptoms before treatment (p=0.7956) nor the association with effectiveness of the therapy (p=0.2051) were found. Conclusions: On the basis of the results of the preliminary study, C1236T of ABCB1 gene have no influence on the predisposition to rDD, the severity of depressive symptoms and the efficiency of antidepressant therapy have not been stated, either.
Streszczenie Wstęp: Według danych Światowej Organizacji Zdrowia depresja dotyka około 350 milionów osób na całym świecie. Jednak pomimo powszechnego występowania, zarówno etiologia tej choroby, jak i przyczyny oporności na leczenie w dalszym ciągu nie są w pełni poznane. Gen ABCB1 koduje glikoproteinę P, która jest jednym z elementów bariery krew-mózg. Główną funkcją białka jest usuwanie związków toksycznych, w tym także leków, co może wskazywać na potencjalny związek między prawidłowym działaniem glikoproteiny P a predyspozycją do rozwoju zaburzeń depresyjnych czy niepowodzeniem terapii lekami przeciwdepresyjnymi. Celem pracy była ocena polimorfizmu pojedynczego nukleotydu (ang. single nucleotide polymorphism - SNP) C1236T genu ABCB1 wśród chorych na zaburzenia depresyjne nawracające (ang. recurrent depressive disorder - rDD) oraz oszacowanie potencjalnego związku tego polimorfizmu z odpowiedzią na terapię lekami przeciwdepresyjnymi. Materiał i metody: Polimorfizm C1236T oceniono w grupie 30 pacjentów, u których zdiagnozowano rDD. Genotyp określono wykorzystując technikę automatycznego sekwencjonowania metodą Sangera. Otrzymane wyniki porównano z wynikami grupy kontrolnej, którą stanowiło 96 dawców krwi z lokalnego banku krwiodawstwa. Wyniki: Nie stwierdzono istotnych statystycznie różnic w częstości występowania poszczególnych genotypów (p=0,0665) i alleli (p=0,1489) polimorfizmu C1236T genu ABCB1 między grupą pacjentów z rDD a grupą kontrolną. Nie wykazano również zależności pomiędzy C1236T a wiekiem w chwili diagnozy rDD (p=0,0807), nasileniem objawów depresji przed rozpoczęciem terapii (p=0,7956) czy skutecznością leczenia przeciwdepresyjnego (p=0,2051). Wnioski: Na podstawie wyników badania wstępnego, stwierdzono brak wpływu polimorfizmu C1236T genu ABCB1 na predyspozycję do rozwoju rDD, nasilenie objawów depresji w chwili diagnozy czy skuteczność terapii przeciwdepresyjnej.
Źródło:
Folia Medica Lodziensia; 2014, 41, 1; 5-15
0071-6731
Pojawia się w:
Folia Medica Lodziensia
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Detection of Plasmodium falciparum chloroquine resistance transporter (PfCRT) mutant gene amongst malaria-infected pregnant women in Calabar, Nigeria
Autorzy:
Monjol, Bernard Ekpan
Useh, Monday Francis
Powiązania:
https://bibliotekanauki.pl/articles/972121.pdf
Data publikacji:
2017
Wydawca:
Polskie Towarzystwo Parazytologiczne
Tematy:
malaria
chloroquine
artemisinin-based combination therapy
microscopy
PCR
PFCRT
Opis:
Chemotherapy is the mainstay in malaria control and management. For some time, chloroquine (CQ) was a drug of choice for the treatment of malaria. It was effective against all forms of malaria, cheap and readily available. The increased resistance of malaria parasites to CQ led to widespread abandonment of the drug in African and Asian countries on the prompting of the World Health Organization. Currently, artemisinin-based combination therapy is the gold standard for the treatment of malaria. This study investigates the presence of the Plasmodium falciparum Chloroquine Resistance Transporter (PfCRT) mutant gene, a molecular marker responsible for CQ resistance in malaria parasites. A total of 369 pregnant women were microscopically screened for malaria infection using thin and thick blood films stained with Giemsa. Subsequently, malaria parasite DNA was extracted from the blood of malaria positive participants. The PfCRT gene was amplified using Polymerase Chain Reaction (PCR). A Restriction Fragment Length Polymorphism analysis of the gene was performed to confirm mutant forms. The results showed that 251 (68.0%) of the participants had Plasmodium falciparum in their blood. Molecular examination revealed the presence of PfCRT mutant genes in 28% of the study population. Notwithstanding the decline in the prevalence of PfCRT T76 mutation since the antimalarial policy change in Nigeria, the 28% prevalence recorded in this study is considered high after ten years of the withdrawal of CQ in the treatment of uncomplicated malaria.
Źródło:
Annals of Parasitology; 2017, 63, 4; 323-330
0043-5163
Pojawia się w:
Annals of Parasitology
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Direct transfer of IL-12 gene into growing Renca tumors.
Autorzy:
Budryk, Magdalena
Wilczyńska, Urszula
Szary, Jarosław
Szala, Stanisław
Powiązania:
https://bibliotekanauki.pl/articles/1044365.pdf
Data publikacji:
2000
Wydawca:
Polskie Towarzystwo Biochemiczne
Tematy:
IL-12 gene
tumor gene therapy
naked DNA
Opis:
We investigated the feasibility of transferring naked plasmid DNA containing a therapeutic gene (IL-12) into mice harboring growing Renca tumors. We found that naked DNA transferred into growing Renca and B16(F10) tumors gives higher expression level of reporter gene than complexes of DNA with DDAB/ DOPE or DC-Chol/DOPE. Transfer of naked DNA carrying the IL-12 gene into growing Renca tumors causes a distinct therapeutic effect that depends on the time span between inoculation of mice with cancer cells and the beginning of the therapy. Therapy started on day 3 resulted in total cure (100%) of mice.
Źródło:
Acta Biochimica Polonica; 2000, 47, 2; 385-391
0001-527X
Pojawia się w:
Acta Biochimica Polonica
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
DNA microarrays - future in oncology research and therapy
Autorzy:
Krol, M.
Pawlowski, K.M.
Otrebska, D.
Motyl, T.
Powiązania:
https://bibliotekanauki.pl/articles/3349.pdf
Data publikacji:
2008
Wydawca:
Instytut Medycyny Wsi
Tematy:
DNA microarray
future
oncology
research
therapy
genomics
gene expression
canine mammary cancer
tumour
human disease
cancer
Źródło:
Journal of Pre-Clinical and Clinical Research; 2008, 02, 2
1898-2395
Pojawia się w:
Journal of Pre-Clinical and Clinical Research
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Efficacy of crizotinib therapy for a patient with non-small cell lung cancer with ALK gene rearrangement – case report and review of current therapeutic options
Autorzy:
Bargiel, J.B.
Cabaj, J.
Chmielewska, I.
Milanowski, J.
Powiązania:
https://bibliotekanauki.pl/articles/2098542.pdf
Data publikacji:
2021
Wydawca:
Instytut Medycyny Wsi
Tematy:
non-small cell lung cancer
crizotinib
therapy
gene rearrangement
tyrosine kinase inhibitor
patient
Opis:
Introduction. Currently, nearly 23,000 cases of lung cancer are diagnosed in Poland annually, of which 5% are cases with rearrangements in the ALK gene. In recent years, tremendous progress has been made in understanding the genetic makeup of this type of cancer, which has enabled the use of new therapies, in particular, molecularly targeted drugs. Crizotinib is the first oral small molecule inhibitor of ALK, MET and ROS1 receptor tyrosine Kinases approved by the European Medicines Agency(EMA). Case report. The paper presents the case of a 62-year-old patient diagnosed with non-small cell lung cancer with rearrangement in the ALK gene in stage IV of the disease. The patient was qualified for treatment with crizotinib under the B6 drug programme. Treatment started in May 2019. During treatment, assessment was made at 3 control points, where the first and second showed a partial response according to the RECIST 1.1 scale; in the next assessment, the response was maintained in the form of disease stabilization.
Źródło:
Journal of Pre-Clinical and Clinical Research; 2021, 15, 3; 151-154
1898-2395
Pojawia się w:
Journal of Pre-Clinical and Clinical Research
Dostawca treści:
Biblioteka Nauki
Artykuł
Wyświetlanie 1-15 z 37

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies